60% of biotech companies discover blocking patents only after significant R&D investment. Our AI maps your patent landscape — white space, freedom-to-operate gaps, and filing priorities — before you spend another dollar.
The Stakes
of biotech companies discover blocking patents after $5M+ R&D spend
PwC Biotech Deals Report, 2024
years average from provisional filing to issued composition-of-matter patent
USPTO Patent Statistics, 2023
valuation premium for companies with strong IP portfolios at Series A
PitchBook Biotech Report, 2024
We map the density of patent activity in your therapeutic area and modality — identifying whether the space is crowded, navigable, or wide open.
We identify freedom-to-operate gaps across composition of matter, method of use, manufacturing process, and biomarker claims.
We find the areas with no or weak patent coverage — the opportunities for your own IP filings and design-around strategies.
We prioritize your filing strategy by commercial value, urgency, and competitive risk — from provisional to PCT to national phase.
We show patent concentration by jurisdiction — where to file first, where the white space is, and where competitors are most active.
We flag the patents that could block your program — with analysis of claim scope, expiry timeline, and design-around feasibility.
Patent Landscape Analysis
~5 minutes. Your program parameters. Our patent database. Mapped in minutes.
Step 1 of 2
Confidentiality: Use a code name only. Do not enter specific compound names, sequences, or proprietary identifiers.
Legal Disclaimer: The Patent Landscape Navigator is provided for strategic decision-support purposes only and does not constitute legal or patent advice. All IP decisions should be independently verified by qualified patent attorneys. © 2026 Bridge BioHealth Consulting LLC.
We use cookies to improve your experience.
We use essential and analytics cookies to operate our platform and understand how visitors use it. See our Privacy Policy for details.